interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Daptomycin

Generic competition · all medicines · read 12 November 2026

Is there a generic of Daptomycin, and who makes it?

Daptomycin appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 16 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 11 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Daptomycin2 dosage-form groups in the Orange Book
16generic makers listed
  1. Daptomycin appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 16 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 11 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Intravenous

Four or more generic makers listed

Brand listed as marketed: Daptomycin. 16 generic makers with 21 generic products listed as marketed; the first generic approval is dated 12 September 2014.

2000200520102015202020252030203520402045016brand 2003Teva Pharmaceuticals Usa Inc, first approval 25 March 2016Xellia Pharmaceuticals Aps, first approval 15 June 2016Fresenius Kabi Usa Llc, first approval 11 April 2018Mylan Laboratories Ltd, first approval 5 June 2018Dr Reddys Laboratories Ltd, first approval 1 May 2019Accord Healthcare Inc, first approval 24 June 2019Be Pharmaceuticals Ag, first approval 26 June 2019Sagent Pharmaceuticals Inc, first approval 15 November 2019Hisun Pharmaceutical Hangzhou Co Ltd, first approval 21 April 2021Meitheal Pharmaceuticals Inc, first approval 29 June 2021Qilu Pharmaceutical Hainan Co Ltd, first approval 24 August 2021Eugia Pharma Specialities Ltd, first approval 2 September 2021Hainan Poly Pharmaceutical Co Ltd, first approval 18 August 2022Aspiro Pharma Ltd, first approval 23 September 2022Mylan Pharmaceuticals Inc A Viatris Co, first approval 7 August 2023Biocon Pharma Ltd, first approval 29 August 2024data datePatent 10357535 listed to expire 11 September 2033Patent 9655946 listed to expire 11 September 2033Patent 12053502 listed to expire 28 August 2038Patent 11759497 listed to expire 28 August 2038Patent 12629337 listed to expire 9 January 2043
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Teva Pharmaceuticals Usa Inc25 March 20161
Xellia Pharmaceuticals Aps15 June 20161
Fresenius Kabi Usa Llc11 April 20181
Mylan Laboratories Ltd5 June 20181
Dr Reddys Laboratories Ltd1 May 20192
Accord Healthcare Inc24 June 20192
Be Pharmaceuticals Ag26 June 20192
Sagent Pharmaceuticals Inc15 November 20191
Hisun Pharmaceutical Hangzhou Co Ltd21 April 20211
Meitheal Pharmaceuticals Inc29 June 20212
Qilu Pharmaceutical Hainan Co Ltd24 August 20211
Eugia Pharma Specialities Ltd2 September 20211

4 more makers are listed in the data.

Patents and exclusivities still listed

  • 11 September 2033Patent 10357535 drug product
  • 11 September 2033Patent 9655946 drug product
  • 28 August 2038Patent 12053502
  • 28 August 2038Patent 11759497 drug product
  • 9 January 2043Patent 12629337 drug product

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Daptomycin In 0.9% Sodium Chloride. No generic is listed as marketed.

20202025203001brand 2023data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.